BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study that examines the durability and broad strain coverage of LHNVD-105, the company’s universal influenza vaccine candidate, at IDWeek 2023. IDWeek will take place in-person in Boston, Massachusetts from October 11-15, 2023.
LHNVD-105 is an unconjugated, multi-epitope peptide-based vaccine formulated with the highly potent adjuvant Army Liposome Formulation with QS-21 (ALFQ). The vaccine is in development to mitigate infections of human and avian influenza viruses.
Poster Title: Unconjugated Multi-epitope Peptides Adjuvanted with ALFQ Induce Durable and Broadly Reactive Antibodies to Human and Avian Influenza Viruses
Presenter: Nimisha Rikhi, PhD., Research Scientist, Microbiology and Immunology Laboratory, Longhorn Vaccines and Diagnostics
Session Title: Adult Vaccines
Session Date: Friday, October 13, 2023
Session Time: 12:15 p.m.-1:30 p.m. ET
Session Location: Hall B+C, Boston Convention and Exhibition Center
IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP).
For more information about Longhorn, visit www.LHNVD.com.
About Longhorn Vaccines and Diagnostics
Longhorn Vaccines and Diagnostics LLC is a closely held One Health company based in Maryland that is developing vaccines and diagnostic tools for worldwide public health concerns and to prevent future pandemics. Since its inception in 2006, Longhorn has focused on developing vaccines and diagnostic tools that can impact a pandemic on a global scale and at all socio-economic levels. Since pandemics flow between humans and animals, Longhorn caters to both in order to surveil, diagnose, prevent and treat the next infectious disease.
Longhorn developed and patented a composite peptide platform for generating vaccines against challenging pathogens, multiple pathogens, and engineering multiple targets for preventing the effects of a disease. LHNVD-105, an adjuvated universal influenza vaccine targeting NA, M1, M2, M2e, HA head and HA stalk, is Longhorn’s lead vaccine candidate. An IND-enabling stage vaccine, LHNVD-105 is expected to enter phase I clinical trials in Q2/Q3 2024. Longhorn has multiple vaccines and monoclonal antibody candidates in pre-clinical testing for viral and respiratory diseases.
